Ann Lab Med.  2025 Mar;45(2):185-198. 10.3343/alm.2024.0178.

CD69 Expression is Negatively Associated With T-Cell Immunity and Predicts Antiviral Therapy Response in Chronic Hepatitis B

• Gu Y
• Bi Y
• Huang Z
• Liao C
• Li X
• Hu H
• Xie H
• Huang Y

• KMID: 2565650
• DOI: http://doi.org/10.3343/alm.2024.0178

Abstract

Background
The function of CD69 expressed on T cells in chronic hepatitis B (CHB) remains unclear. We aimed to elucidate the roles of CD69 on T cells in the disease process and in antiviral therapy for CHB.
Methods
We enrolled 335 treatment-naive patients with CHB and 93 patients with CHB on antiviral therapy. CD69, antiviral cytokine production by T cells, T-helper (Th) cells, and inhibitory molecules of T cells were measured using flow cytometry, and clinical-virological characteristics were examined dynamically during antiviral therapy.
Results
CD69 expression on CD3+, CD4+, and CD8+ T cells was the lowest in the immune-active phase and was negatively correlated with liver transaminase activity, fibrosis features, inflammatory cytokine production by T cells, and Th-cell frequencies but positively with inhibitory molecules on T cells. CD69 expression on CD3+, CD4+, and CD8+ T cells decreased after 48 weeks of antiviral therapy, and patients with hepatitis B e antigen (HBeAg) seroconversion in week 48 showed lower CD69 expression on T cells at baseline and week 48. The area under the ROC curve of CD69 expression on T cells at baseline for predicting HBeAg seroconversion in week 48 was 0.870, the sensitivity was 0.909, and the specificity was 0.714 (P = 0.002).
Conclusions
CD69 negatively regulates T-cell immunity during CHB, and its expression decreases with antiviral therapy. CD69 expression predicts HBeAg seroconversion in week 48. CD69 may play an important negative role in regulating T cells and affect the efficacy of antiviral therapy.

Keyword

Antiviral agents; CD69; Chronic hepatitis B; T cell; Therapy

Figure

• 

  Fig. 1 CD69 expression on T cells and their subsets in treatment-naive patients with CHB and HCs. (A) CD69 levels on CD3+, CD4+ and CD8+ T cells in patients with CHB and HCs. (B–C) CD69 levels on T cells and the subset cells in patients with CHB in the IT, IA, IC, and GZ phases and HCs. (D) CD69 MFI of CD3+, CD4+ and CD8+ T cells in patients with CHB and HCs. (E) CD69 MFI of T cells and their subsets in patients with CHB in the IT, IA, IC and GZ phases and HCs. None of the continuous variables conformed to the normal distribution. P-values were calculated using the Mann–Whitney U test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Abbreviations: MFI, mean fluorescence intensity; CHB, chronic hepatitis B; HC, healthy control; IT, immune-tolerant; IA, immune-active; IC, inactive CHB; GZ, gray zone.

• 

  Fig. 2 Correlation between CD69 and antiviral cytokine production by T cells. Levels of (A) IL-2, (B) IFN-γ, (C) TNF-α, (D) IL-6, and (E) granzyme B produced by CD3+, CD4+ and CD8+ T cells in the CD69high and CD69low groups, and correlations between these antiviral cytokines and CD69 levels on CD3+, CD4+ and CD8+ T cells. None of the continuous variables conformed to the normal distribution. Differences were analyzed using the Mann–Whitney U test. Spearman correlation was used for correlation analysis. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Abbreviations: IL, interleukin; IFN-γ, interferon-gamma; ns, non-significant; TNF-α, tumor necrosis factor alpha.

• 

  Fig. 3 Correlation between CD69 and Th-cell levels. Levels of (A) Th1, (B) Th2, (C) Th17, (D) Th22, and (E) Tfh cells in function of CD3+, CD4+, and CD8+ T cells in the CD69high and CD69low groups, and correlations between these Th cells and CD69 levels on CD3+, CD4+ and CD8+ T cells. None of the continuous variables conformed to the normal distribution. Differences were analyzed using the Mann–Whitney U test. Spearman correlation was used for correlation analysis. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Abbreviations: Th, T-helper; Tfh, T follicular helper.

• 

  Fig. 4 Correlation between CD69 and inhibitory molecule production by T cells. Levels of (A) PD-1, (B) CTLA-4, (C) LAIR-1, and (D) LAG-3 on CD3+, CD4+ and CD8+ T cells in the CD69high and CD69low groups, and correlations between these inhibitory molecules and CD69 levels on CD3+, CD4+, and CD8+ T cells. None of the continuous variables conformed to the normal distribution. Differences were analyzed using the Mann–Whitney U test. Spearman correlation was used for correlation analysis. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Abbreviations: PD-1, programmed death receptor 1; CTLA-4, cytotoxic T lymphocyte-associated antigen-4; ns, non-significant; LAIR-1, leukocyte-associated Ig-like receptor-1; LAG-3, lymphocyte activation gene-3.

• 

  Fig. 5 CD69 levels on T cells decrease after 48 weeks of antiviral therapy and predict HBeAg seroconversion. (A) Changes in ALT, HBsAg, and HBV DNA levels after antiviral therapy for 48 weeks. (B, C) Changes in CD69 levels on CD3+, CD4+, and CD8+ T cells after 48 weeks of antiviral therapy based on ETV and Peg-IFN treatment, respectively. (D) Differences in CD69 expression on T cells at baseline and in week 48 between patients who achieved HBeAg seroconversion and those who did not for ETV and Peg-IFN treatment, respectively. (E) ROC analysis of the combined (ROC1) or solo expression of CD69 on CD3+ (ROC2), CD4+ (ROC3) and CD8+ (ROC4) T cells at baseline for predicting HBeAg seroconversion in week 48 in ETV-treated patients. None of the continuous variables conformed to the normal distribution Differences were analyzed using Wilcoxon matched-pairs rank test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Abbreviations: ALT, alanine transaminase; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; ETV, entecavir; PEG: Peg-interferon; HBeAg, hepatitis B e antigen; ns, non-significant; AUC: area under the ROC curve; w, weeks.

Reference

References

1. Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, et al. 2019; A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 4:545–58. DOI: 10.1016/S2468-1253(19)30119-0. PMID: 30981686. PMCID: PMC6732795.

2. Bertoletti A, Wang FS. 2015; Overview of the special issue on HBV immunity. Cell Mol Immunol. 12:253–4. DOI: 10.1038/cmi.2015.24. PMID: 25864914. PMCID: PMC4654325.

3. Bertoletti A, Ferrari C. 2016; Adaptive immunity in HBV infection. J Hepatol. 64(S):S71–83. DOI: 10.1016/j.jhep.2016.01.026. PMID: 27084039.

4. Sancho D, Gómez M, Sánchez-Madrid F. 2005; CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 26:136–40. DOI: 10.1016/j.it.2004.12.006. PMID: 15745855.

5. Hamann J, Fiebig H, Strauss M. 1993; Expression cloning of the early activation antigen CD69, a type II integral membrane protein with a C-type lectin domain. J Immunol. 150:4920–7. DOI: 10.4049/jimmunol.150.11.4920. PMID: 8496594.

6. Testi R, D'Ambrosio D, De Maria R, Santoni A. 1994; The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today. 15:479–83. DOI: 10.1016/0167-5699(94)90193-7. PMID: 7945773.

7. Moretta A, Poggi A, Pende D, Tripodi G, Orengo AM, Pella N, et al. 1991; CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta. J Exp Med. 174:1393–8. DOI: 10.1084/jem.174.6.1393. PMID: 1720808. PMCID: PMC2119034.

8. Borrego F, Robertson MJ, Ritz J, Peña J, Solana R. 1999; CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology. 97:159–65. DOI: 10.1046/j.1365-2567.1999.00738.x. PMID: 10447727. PMCID: PMC2326810.

9. Cebrián M, Yagüe E, Rincón M, López-Botet M, de Landázuri MO, Sánchez-Madrid F. 1988; Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. J Exp Med. 168:1621–37. DOI: 10.1084/jem.168.5.1621. PMID: 2903209. PMCID: PMC2189112.

10. Testi R, Phillips JH, Lanier LL. 1989; T cell activation via Leu-23 (CD69). J Immunol. 143:1123–8. DOI: 10.4049/jimmunol.143.4.1123. PMID: 2501389.

11. de la Fuente H, Cruz-Adalia A, Martinez Del Hoyo G, Cibrián-Vera D, Bonay P, Pérez-Hernández D, et al. 2014; The leukocyte activation receptor CD69 controls T cell differentiation through its interaction with galectin-1. Mol Cell Biol. 34:2479–87. DOI: 10.1128/MCB.00348-14. PMID: 24752896. PMCID: PMC4054309.

12. Martín P, Gómez M, Lamana A, Cruz-Adalia A, Ramírez-Huesca M, Ursa MA, et al. 2010; CD69 association with Jak3/Stat5 proteins regulates Th17 cell differentiation. Mol Cell Biol. 30:4877–89. DOI: 10.1128/MCB.00456-10. PMID: 20696842. PMCID: PMC2950549.

13. Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PTF, et al. 2008; Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med. 205:2111–24. DOI: 10.1084/jem.20072076. PMID: 18695005. PMCID: PMC2526205.

14. Fletcher SP, Chin DJ, Ji Y, Iniguez AL, Taillon B, Swinney DC, et al. 2012; Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology. 56:820–30. DOI: 10.1002/hep.25730. PMID: 22431061. PMCID: PMC3401284.

15. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. 2018; Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 67:1560–99. DOI: 10.1002/hep.29800. PMID: 29405329. PMCID: PMC5975958.

16. Gu Y, Li X, Gu L, Lian Y, Wang K, Chen Y, et al. 2020; An immuno-clinic score model for evaluating T cell immunity and predicting early antiviral therapy effectiveness in chronic hepatitis B. Aging (Albany, NY). 12:26063–79. DOI: 10.18632/aging.202274. PMID: 33401245. PMCID: PMC7803537.

17. Freeman BE, Hammarlund E, Raué HP, Slifka MK. 2012; Regulation of innate CD8+ T-cell activation mediated by cytokines. Proc Natl Acad Sci U S A. 109:9971–6. DOI: 10.1073/pnas.1203543109. PMID: 22665806. PMCID: PMC3382521.

18. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. 1999; Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:708–12. DOI: 10.1038/44385. PMID: 10537110.

19. Li L, Yang B, Zhang X, Lao S, Changyou W. 2014; Mycobacterium tuberculosis-specific polyfunctional cytotoxic CD8+ T cells express CD69. Tuberc (Edinb). 94:219–25. DOI: 10.1016/j.tube.2013.12.007. PMID: 24566284.

20. Martín P, Gómez M, Lamana A, Matesanz Marín A, Cortés JR, Ramírez-Huesca M, et al. 2010; The leukocyte activation antigen CD69 limits allergic asthma and skin contact hypersensitivity. J Allergy Clin Immunol. 126:355–65. 65 e1–3. DOI: 10.1016/j.jaci.2010.05.010. PMID: 20621339.

21. Cruz-Adalia A, Jiménez-Borreguero LJ, Ramírez-Huesca M, Chico-Calero I, Barreiro O, López-Conesa E, et al. 2010; CD69 limits the severity of cardiomyopathy after autoimmune myocarditis. Circulation. 122:1396–404. DOI: 10.1161/CIRCULATIONAHA.110.952820. PMID: 20855659.

22. Shiow LR, Rosen DB, Brdicková N, Xu Y, An J, Lanier LL, et al. 2006; CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature. 440:540–4. DOI: 10.1038/nature04606. PMID: 16525420.

23. Jiménez-Fernández M, Rodríguez-Sinovas C, Cañes L, Ballester-Servera C, Vara A, Requena S, et al. 2022; CD69-oxLDL ligand engagement induces programmed cell death 1 (PD-1) expression in human CD4 + T lymphocytes. Cell Mol Life Sci. 79:468. DOI: 10.1007/s00018-022-04481-1. PMID: 35930205. PMCID: PMC9355928.

24. Gu Y, Lian Y, Gu L, Chen L, Li X, Zhou L, et al. 2019; Correlations between cytokines produced by T cells and clinical-virological characteristics in untreated chronic hepatitis B patients. BMC Infect Dis. 19:216. DOI: 10.1186/s12879-019-3853-2. PMID: 30832595. PMCID: PMC6398217. PMID: f8871d66729948178e22893635048b32.

25. Khanam A, Chua JV, Kottilil S. 2021; Immunopathology of chronic hepatitis B infection: role of innate and adaptive immune response in disease progression. Int J Mol Sci. 22:5497. DOI: 10.3390/ijms22115497. PMID: 34071064. PMCID: PMC8197097.

26. Cibrián D, Sánchez-Madrid F. 2017; CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 47:946–53. DOI: 10.1002/eji.201646837. PMID: 28475283. PMCID: PMC6485631.

27. Yu L, Zhou B, Zhu Y, Li L, Zhong Y, Zhu L, et al. 2023; HSF1 promotes CD69⁺ Treg differentiation to inhibit colitis progression. Theranostics. 13:1892–905. DOI: 10.7150/thno.78078. PMID: 37064870. PMCID: PMC10091886.

28. Yang FA-OX, Yu XA-O, Zhou C, Mao R, Zhu M, Zhu H, et al. 2019; Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. PLoS Pathog. 15:e1007690. DOI: 10.1371/journal.ppat.1007690. PMID: 30998767. PMCID: PMC6472891. PMID: dcaba0a3c77e45fda0e7dc014a8dcc97.

29. Tang R, Lei Z, Wang X, Qi Q, He J, Liu D, et al. 2020; Hepatitis B envelope antigen increases Tregs by converting CD4⁺CD25- T cells into CD4⁺CD25⁺ Foxp3⁺ Tregs. Exp Ther Med. 20:3679–86. DOI: 10.3892/etm.2020.9107.

30. Chen LM, Fan XG, Ma J, He B, Jiang YF. 2017; Molecular mechanisms of HBeAg in persistent HBV infection. Hepatol Int. 11:79–86. DOI: 10.1007/s12072-016-9734-5. PMID: 27193024.

31. Ma Q, Dong X, Liu S, Zhong T, Sun D, Zong L, et al. 2020; Hepatitis B e antigen induces NKG2A⁺ natural killer cell dysfunction via regulatory T cell-derived interleukin 10. In: Chronic hepatitis B virus infection. Front Cell Dev Biol. 8:421. DOI: 10.3389/fcell.2020.00421. PMID: 32582704. PMCID: PMC7283553. PMID: a94f719efa224845938f50e31273ff79.

32. Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, et al. 2019; Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin Cancer Res. 25:4663–73. DOI: 10.1158/1078-0432.CCR-18-4142. PMID: 31053602. PMCID: PMC7444693.

33. Huang W, He W, Shi X, Ye Q, He X, Dou L, et al. 2020; Mucosal-associated invariant T-cells are severely reduced and exhausted in humans with chronic HBV infection. J Viral Hepat. 27:1096–107. DOI: 10.1111/jvh.13341. PMID: 32510704.

34. Cortés JR, Sánchez-Díaz R, Bovolenta ER, Barreiro O, Lasarte S, Matesanz-Marín A, et al. 2014; Maintenance of immune tolerance by Foxp3⁺ regulatory T cells requires CD69 expression. J Autoimmun. 55:51–62. DOI: 10.1016/j.jaut.2014.05.007. PMID: 24934597. PMCID: PMC4625610.

35. Hossen MM, Ma Y, Yin Z, Xia Y, Du J, Huang JY, et al. 2023; Current understanding of CTLA-4: from mechanism to autoimmune diseases. Front Immunol. 14:1198365. DOI: 10.3389/fimmu.2023.1198365. PMID: 37497212. PMCID: PMC10367421. PMID: 0694dee8012245ecaea1ae8a552ab50c.

36. Walker LSK. 2013; Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun. 45:49–57. DOI: 10.1016/j.jaut.2013.06.006. PMID: 23849743. PMCID: PMC3989116.

37. Goronzy JJ, Weyand CM. 2013; Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 14:428–36. DOI: 10.1038/ni.2588. PMID: 23598398. PMCID: PMC4183346.

38. Wherry EJ, Kurachi M. 2015; Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 15:486–99. DOI: 10.1038/nri3862. PMID: 26205583. PMCID: PMC4889009.